- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Führungswechsel bei Valion Bio: Dean Zikria wird Interims-CEO | 2 | Investing.com Deutsch | ||
| Mi | Valion Bio, Inc.: Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions | 243 | ACCESS Newswire | Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23... ► Artikel lesen | |
| Mi | Valion Bio, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| VALION BIO Aktie jetzt für 0€ handeln | |||||
| Di | Valion Bio regains Nasdaq minimum bid price compliance | 2 | Investing.com | ||
| Di | Valion Bio erfüllt wieder NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| Di | Valion Bio, Inc.: Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule | 191 | ACCESS Newswire | Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company) announced... ► Artikel lesen | |
| 01.09. | Valion Bio, Inc.: Valion Bio Announces Changes to Management and Board of Directors | 339 | ACCESS Newswire | Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets:... ► Artikel lesen | |
| 27.08. | Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split | 561 | ACCESS Newswire | SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock... ► Artikel lesen | |
| 27.08. | Valion Bio announces 1-for-25 reverse stock split | 2 | Investing.com | ||
| 27.08. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.08. | Valion Bio mit Führungswechsel und neuer Finanzierung | 2 | Investing.com Deutsch | ||
| 17.08. | Valion Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08. | Valion Bio, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 13.08. | Valion Bio, Inc.: Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase | 611 | ACCESS Newswire | Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry... ► Artikel lesen | |
| 12.08. | Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury | 929 | ACCESS Newswire | AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early FallStudy drug delivered • IACUC approval secured • Safety study planned... ► Artikel lesen | |
| 20.07. | Sheba Medical Center to evaluate Valion Bio's Entolimod in trial | 4 | Investing.com | ||
| 20.07. | Sheba Medical Center prüft Entolimod von Valion Bio in klinischer Studie | 1 | Investing.com Deutsch | ||
| 17.07. | Valion Bio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.07. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALIGNMENT HEALTHCARE | 7,680 | +0,13 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| BILLIONTOONE | 124,87 | -0,02 % | Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently | ||
| BRIGHTSPRING HEALTH SERVICES | 55,99 | -0,05 % | BrightSpring auf Bernstein-Gesundheitsforum: Wachstum steht noch am Anfang | ||
| GENEDX | 88,45 | -0,03 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| AVEANNA HEALTHCARE | 12,380 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 11,800 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| PROGYNY | 25,980 | +0,04 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| PROFUSA | 3,030 | 0,00 % | Profusa receives ISO 13485 certification for quality system | ||
| GLUCOTRACK | 2,575 | -0,19 % | GlucoTrack Stock Rises 27% After Public Offering Announcement | ||
| HEARTFLOW | 48,660 | 0,00 % | Canaccord raises HeartFlow stock price target on plaque analysis survey | ||
| PRIVIA HEALTH GROUP | 19,400 | +0,05 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 17,510 | +0,06 % | Procept BioRobotics verlängert Kreditlaufzeit mit CIBC um ein Jahr | ||
| BETA BIONICS | 21,740 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| CLEARPOINT NEURO | 14,610 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Reports Second Quarter 2026 Results | Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT)... ► Artikel lesen | |
| STARLING ONCOLOGY INSTITUTE | 6,515 | +0,08 % | The Oncology Institute Rebrands as Starling Oncology | CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or "the Company"), one of the largest value-based oncology groups in the United States, announced today that... ► Artikel lesen |
VALION BIO INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALION BIO INC finden Sie auf Wallstreet Online.